Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)
CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Belo Horizonte-MG, Brazil, 30150270
- Altana Pharma/Nycomed
-
Blumenau - SC, Brazil, 89010906
- Altana Pharma/Nycomed
-
Botucatu - SP, Brazil, 18610970
- Altana Pharma/Nycomed
-
Campinas - SP, Brazil, 13013101
- Altana Pharma/Nycomed
-
Campinas - Sao Paulo, Brazil, 13070040
- Altana Pharma/Nycomed
-
Curitiba - PR, Brazil, 80060
- Altana Pharma/Nycomed
-
Ilha do Fundao - Rio de Janeiro - RJ, Brazil, 21941590
- Altana Pharma/Nycomed
-
Pinheiros Sao Paulo - SP, Brazil, 1246-000
- Altana Pharma/Nycomed
-
Porto Alegre - RS, Brazil, 90035003
- Altana Pharma/Nycomed
-
Porto Alegre-RS, Brazil, 90020090
- Altana Pharma/Nycomed
-
Porto Alegre-RS, Brazil, 90610000
- Altana Pharma/Nycomed
-
Ribeirao Preto-SP, Brazil, 14048900
- Altana Pharma/Nycomed
-
Salvador-BA, Brazil, 41256900
- Altana Pharma/Nycomed
-
Sao Paulo, Brazil, 4024002
- Altana Pharma/Nycomed
-
-
-
-
-
Bad Schwalbach, Germany, 65307
- Altana Pharma/Nycomed
-
Burg, Germany, 39288
- Altana Pharma/Nycomed
-
Gardelegen, Germany, 39638
- Altana Pharma/Nycomed
-
Königstein, Germany, 61462
- Altana Pharma/Nycomed
-
Lübeck, Germany, 23569
- Altana Pharma/Nycomed
-
Lüdenscheid, Germany, 58507
- Altana Pharma/Nycomed
-
Lütjenburg, Germany, 24321
- Altana Pharma/Nycomed
-
Nieder-Olm, Germany, 55268
- Altana Pharma/Nycomed
-
Oelde, Germany, 59302
- Altana Pharma/Nycomed
-
Wiesbaden, Germany, 65189
- Altana Pharma/Nycomed
-
Wolmirstedt, Germany, 39326
- Altana Pharma/Nycomed
-
-
-
-
-
Bydgoszcz, Poland, 85-681
- Altana Pharma/Nycomed
-
Inowroclaw, Poland, 88-100
- Altana Pharma/Nycomed
-
Poznan, Poland, 60479
- Altana Pharma/Nycomed
-
Siemianowice Slaskie, Poland, 41-100
- Altana Pharma/Nycomed
-
Torun, Poland, 87-100
- Altana Pharma/Nycomed
-
Tychy, Poland, 43-100
- Altana Pharma/Nycomed
-
-
-
-
-
Amanzimtoti, South Africa, 4126
- Altana Pharma/Nycomed
-
Berea, Durban, South Africa, 4000
- Altana Pharma/Nycomed
-
Bloemfontein, South Africa, 9317
- Altana Pharma/Nycomed
-
Bloemfontein, South Africa, 9301
- Altana Pharma/Nycomed
-
Cape Town, South Africa, 7530
- Altana Pharma/Nycomed
-
Durban, South Africa, 4001
- Altana Pharma/Nycomed
-
Goodwood, South Africa, 7460
- Altana Pharma/Nycomed
-
Johannesburg, South Africa, 2033
- Altana Pharma/Nycomed
-
Overport, Durban, South Africa, 4001
- Altana Pharma/Nycomed
-
Panorama, South Africa, 7500
- Altana Pharma/Nycomed
-
Pinetown, South Africa, 4013
- Altana Pharma/Nycomed
-
Port Elizabeth, South Africa, 6001
- Altana Pharma/Nycomed
-
Pretoria, South Africa, 48
- Altana Pharma/Nycomed
-
Somerset-West, South Africa, 7130
- Altana Pharma/Nycomed
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main Inclusion Criteria:
- Written informed consent
- Endoscopically confirmed GERD (Los Angeles classification A-D)
- Patients whose compliance is expected to be high with respect to the completion of the questionnaires
Main Exclusion Criteria:
- Other gastrointestinal diseases
- Severe concomitant diseases
- Proton pump inhibitors (PPIs) during last 14 days before start
- H2 receptor antagonists, prokinetics during last 7 days before study start
- Helicobacter pylori (H. pylori) eradication during last 28 days before study start
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
time to endoscopic relapse and/or unwillingness to continue due to GERD related symptoms
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
safety
|
|
further efficacy criteria
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Werner Janssen, MD, 23569 Lübeck, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Intestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Esophagitis
- Peptic Ulcer
- Duodenal Diseases
- Gastroesophageal Reflux
- Esophagitis, Peptic
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Pantoprazole
Other Study ID Numbers
Other Study ID Numbers
- BY1023/M3-342
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.